Intellective Bio is a biopharmaceutical CDMO committed to accelerating product development and commercialization. With its broad expertise in R&D and modern infrastructure, the company offers flexible scaling from 1 to >15,000 liters. Its multiple cGMP plants in Suzhou, China are optimized for regulatory markets such as US, Europe, and China as well as other global territories.
The company's global regulatory professionals facilitate registration and commercialization strategies in major pharmaceutical markets. Notably, for product launches in China, Intellective Bio helps international clients rapidly enter the Chinese market through its capabilities in production and regulatory affairs.
Specializing in manufacturing antibodies, ADCs, fusion proteins, and recombinant proteins, Intellective Bio aims to be the one-stop CDMO partner. Founded in 2018, the company recently secured a CNY500.00M Series C investment on 05 August 2022, with Gaorong Capital, CNCB Capital, Founder Securities Co., Ltd., and Fuho Capital as the investors. With its slogan "Your Trusted Development & Manufacturing Partner," Intellective Bio is poised to create infinite possibilities in the Biopharma, Biotechnology, and Pharmaceutical industries.